Trial Profile
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Bronchiolitis obliterans
- Focus Therapeutic Use
- 06 Mar 2024 Planned End Date changed from 1 Dec 2023 to 31 Jul 2024.
- 12 Dec 2023 Results assessing effects of Ruxolitinib for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 25 Oct 2023 Status changed from recruiting to active, no longer recruiting.